We present the case of a -year-old man with longstanding, previously well-controlled type diabetes who developed acute hyperglycemia. His insulin requirements, via his insulin pump, increased to nearly five times his typical daily dose. e patient was admitted for evaluation and treatment and started on an insulin infusion. He had minimal insulin requirements with the insulin infusion. History revealed recent use of a super potent topical corticosteroid for a psoriasis flare. e patient was transitioned back to his insulin pump, using his prior to admission settings. He was advised to discontinue using his topical corticosteroid. He had no further hyperglycemic episodes. e clinical presentation is suggestive of corticosteroid-induced hyperglycemia, suggesting that clinically significant changes can occur even with short duration use, particularly with high potency steroids used. is is to our knowledge the first case reported in which the patient required a very significant amount of extra insulin (nearly five times his typical total daily dose) a er using high potency topical steroid cream. is case highlights the potentially detrimental effect of topical corticosteroid use in patients with diabetes.
Introduction
Systemic/oral administration of corticosteroids can induce or worsen hyperglycemia; however, there are limited reports about topical formulations of corticosteroids causing hyperglycemia. Here we report a case of acute hyperglycemia related to topical corticosteroid use in a patient with longstanding, well-controlled diabetes.
Case Presentation
We cared for a -year-old man with a -year history of type diabetes. He had used an insulin pump for years with a current daily dose of units of insulin. His hemoglobin A C values had ranged from . to . % in the last ten years.
e day prior to admission, the patient developed sudden persistent hyperglycemia. He required units of insulin injections within hours, in addition to the units of basal insulin via his pump. His glucose finally decreased to mg/dl six hours before presentation to the emergency department (see Figure ) . He had normal vitals on presentation. Evaluation, including complete blood count, chemistry panel, blood cultures, and chest radiograph, was normal. Cortisol was not measured.
Upon obtaining further history, the patient reported being in his usual state of health except for a psoriasis flare for which he had used fluocinonide . % cream in the two days prior to presentation. Although he had used a small amount of cream on his hands before, this time he applied the cream to a larger area, including his abdomen, twice a day, using occlusive techniques to increase effectiveness. While hospitalized, the patient was kept on an insulin infusion, requiring . -units/hour. On hospital day , he was transitioned to his insulin pump using his prior-to-admission settings. He was discharged home and advised to discontinue using the fluocinonide cream. On outpatient follow-up, he did not report further hyperglycemia. 
Discussion
e clinical presentation is suggestive of corticosteroidinduced hyperglycemia. We know that systemic/oral administration of corticosteroids can induce or worsen hyperglycemia; however, there are limited reports about topical use causing hyperglycemia. Topical corticosteroids are classified by potency from class I (super potent) to class VII (least potent) [ ]. e fluocinonide . % cream that our patient used is in class I. It has been hypothesized that topical corticosteroids cause hyperglycemia through increasing alanine transport, thereby facilitating hepatic gluconeogenesis, increasing enzymatic activity, and causing a relative insulin resistance [ ].
Gomez and Frost reported two patients with abnormal glucose tolerance tests who developed postprandial hyperglycemia with topical administration of high potency corticosteroid creams [ ]. Two other patients, despite also having abnormal pretreatment glucose tolerance tests, had no changes in postprandial glucose values. All patients had Case Reports in Endocrinology decreased levels of measured cortisol, suggesting clinically significant systemic effects of the topical corticosteroids. Hongo et al. described an elderly man with longstanding diabetes who was diagnosed with psoriasis [ ] and switched from oral to topical corticosteroid therapy. His glycemic control worsened and he required a % increase in total daily insulin dose (Table ) . Kahara et al. reported the case of a patient treated for oral lichen planus with a class VII (lowest potency) steroid on his oral mucosa.
e patient developed new onset diabetes that required initiation of an oral anti-diabetes medication for several months (Table ) Although there are limited data about topical corticosteroid therapy causing alterations in glucose metabolism, it appears that clinically significant changes can occur even with short duration use, particularly with high potency steroids used with occlusive techniques for increased effect. is is to our knowledge the first case reported in which the patient required a very significant amount of extra insulin (nearly five times his typical total daily dose) a er using high potency topical steroid cream. Hence, clinicians need to be aware of the potentially detrimental effect of topical corticosteroid use in patients with diabetes.
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